SS
SUPN icon

SBI Securities’s Supernus Pharmaceuticals SUPN Stock Holding History

SBI Securities’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93 Hold
2
– – ﹤0.01% 3527
2026
Q1 		$103 Sell
2
-2
-50% -$102 ﹤0.01% 3399
2025
Q4 		$199 Buy
4
+2
+100% +$97 ﹤0.01% 3212
2025
Q3 		$96 Hold
2
– – ﹤0.01% 3531
2025
Q2 		$63 Hold
2
– – ﹤0.01% 3672
2025
Q1 		$66 Hold
2
– – ﹤0.01% 3574
2024
Q4 		$72 Buy
+2
New +$70 ﹤0.01% 3550

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

SBI Securities's SUPN Position: Q2 2026 in Review

SBI Securities held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 2 shares worth $93. The position accounts for ﹤0.01% of the portfolio, ranked #3527.

SBI Securities first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $199 in Q4 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • SBI Securities held 2 shares of Supernus Pharmaceuticals worth $93 as of Q2 2026.
  • SBI Securities left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3527 holding.
  • SBI Securities first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Supernus Pharmaceuticals position peaked at $199 in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.